Skip to main content

Adriana Palom Agusti

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Adriana Palom Agusti

Institutions of which they are part

Postdoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Maria Buti Ferret, Montserrat Gomez Perez, Judit Romero Vico, Josep Quer Sivila, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Daniel Martinez Vazquez, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Meritxell Ventura Cots, Ares Aurora Villagrasa Vilella, Emma Bigas Alsina, Carolina Campos Martinez, Macarena Simon-Talero Horga, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 30/06/2025

Impact of HLA haplotypes and HDV viremia in developing of clinical events and quality of life of patients with chronic hepatitis delta.

IP: Maria Buti Ferret
Collaborators: Maria Jose Herrero Mata, Ana Barreira Diaz, Maria del Mar Riveiro Barciela, Jordi Llaneras Artigues, Adriana Palom Agusti
Funding agency: Instituto de Salud Carlos III
Funding: 117370
Reference: PI20/01692
Duration: 01/01/2021 - 30/06/2025

Estudio prospectivo para identificar nuevos marcadores plasmáticos de replicación viral en pacientes con hepatitis crónica por virus de la hepatitis B (VHB) y/o Delta (VHD)

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela, Adriana Palom Agusti, Maria Francesca Cortese
Funding agency: Instituto de Salud Carlos III
Funding: 224757.5
Reference: PI17/02233
Duration: 01/01/2018 - 31/12/2021

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Laura Conesa Milian

Laura Conesa Milian

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Villagrasa Vilella, Ares Aurora

Villagrasa Vilella, Ares Aurora

Senior researcher
Liver Diseases
Read more
Vazquez Sanchez, Angel

Vazquez Sanchez, Angel

Maintenance staff and general services
Cardiovascular Diseases
Read more
Marti Martinez, Sheila

Marti Martinez, Sheila

Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.